2024 年至 2031 年局部给药市场（依产品、给药途径、最终使用者和地区划分）

局部给药市场评估 - 2024-2031

局部和标靶化给药方法的需求正在推动局部给药市场的发展，这些方法具有许多优势，例如可直接作用于患处、减少全身副作用以及提高患者依从性。根据 Verified Market Research 分析师预测，到 2031 年，局部给药市场规模将达到 1,779.7 亿美元，低于 2024 年预测的 1,091.6 亿美元。

新兴的製剂技术市场正在显着推动局部用药市场的成长。这些技术进步正在提高活性药物成分的渗透性和疗效，为各种皮肤病提供更有效的治疗选择，并推动药物输送系统的创新，这将推动该市场在2024年至2031年间以6.3%的复合年增长率增长。

局部给药市场：定义/概述

局部给药是指将药物直接作用于皮肤或黏膜以治疗局部疾病。这种方法可以实现个人化治疗，同时减少整体放射暴露。乳膏、软膏、凝胶、洗剂和经皮吸收贴片是最常见的局部用药剂型。局部给药常用于治疗痤疮、湿疹和牛皮癣等皮肤疾病。它也用于将药物输送至眼、鼻、耳和生殖器。其主要优点包括提高患者依从性、减少副作用以及避免首过代谢。

哪些因素推动了局部给药市场的成长？

皮肤病患病率的上升是局部给药市场的主要驱动力。根据《研究皮肤病学杂誌》发表的《全球疾病负担》报告，2019年全球有19亿人患有皮肤病。美国皮肤病学会的数据显示，痤疮是美国最常见的皮肤问题，每年影响5,000万人。皮肤问题的日益普遍需要有效的局部治疗，这推动了对增强局部给药系统的需求。

全球老龄人口的成长对局部用药市场产生了重大影响。根据世界卫生组织 (WHO) 的数据，2015 年至 2050 年期间，全球 60 岁及以上人口的比例将几乎翻一番，从 12% 增加到 22%。老年人容易罹患各种皮肤问题和慢性疾病，而这些疾病可以透过局部用药治疗。例如，美国国立卫生研究院 (NIH) 估计，超过 90% 的 65 岁及以上人口至少患有一种慢性疾病，其中许多可以透过局部用药治疗。

此外，局部给药技术的进步正在推动市场扩张。 2019年，美国食品药物管理局(FDA) 批准了48种新药，其中许多采用了局部製剂等新型给药机制。例如，FDA药品评估与研究中心 (CDER) 报告称，从2015年到2019年，皮肤病药物占所有新药认证的近8%，其中许多药物采用了创新的局部给药系统。这一发展显示对新型局部给药系统的需求日益增长。

局部给药市场面临的主要挑战是什么？

某些製剂难以成功穿透皮肤屏障，这是局部给药市场面临的主要障碍之一。皮肤作为保护屏障，阻碍了许多活性药物成分 (API) 的正常吸收。这种限制影响了局部治疗的疗效，尤其是对于分子量较大或脂溶性较差的药物，并限制了其临床应用。

此外，局部给药市场的成长也因口服和注射等替代给药方式日益激烈的竞争而受到进一步阻碍。这些替代给药方式能够更快地起效，覆盖范围更广，在某些情况下更具吸引力。因此，与局部治疗相比，医疗保健提供者和患者越来越倾向于选择这些方法。

目录

第一章 引言

• 市场定义
• 市场区隔
• 调查方法

第二章执行摘要

• 主要发现
• 市场概况
• 市集亮点

第三章 市场概况

• 市场规模和成长潜力
• 市场趋势
• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析

第四章局部给药市场（依产品）

• 半固态製剂
• 液体製剂
• 固态剂型
• 经皮製剂

第五章局部给药市场（依给药途径）

• 经皮
• 眼科
• 鼻腔
• 直肠
• 阴道

第六章 区域分析

• 北美洲
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 英国
• 德国
• 法国
• 义大利
• 亚太地区
• 中国
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中东和非洲
• 南非
• 沙乌地阿拉伯
• 阿拉伯聯合大公国

第七章市场动态

• 市场驱动因素
• 市场限制
• 市场机会
• COVID-19 市场影响

第八章 竞争态势

• 主要企业
• 市占率分析

第九章：公司简介

• Hisamitsu Pharmaceuticals
• Bayer AG
• Novartis AG
• Galderma Holding SA
• GlaxoSmithKline PLC
• Johnson & Johnson Private Limited
• Bausch Health Companies Inc.
• Cipla Limited
• 3M Company
• Merck & Co., Inc.
• Crescita Therapeutics Inc.
• Boehringer Ingelheim International GmbH
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Glenmark Pharmaceuticals Ltd.

第十章：市场展望与机会

• 新兴技术
• 未来市场趋势
• 投资机会

第十一章 市场展望 附录

• 简称列表
• 来源和参考文献

Topical Drug Delivery Market Valuation - 2024-2031

The need for localized and targeted drug delivery methods that provide benefits like direct application to the affected area, reduced systemic side effects, and improved patient compliance has propelled the topical drug delivery market. According to the analyst from Verified Market Research, the topical drug delivery market is estimated to reach a valuation of USD 177.97 Billion by 2031 over the forecast subjugating around USD 109.16 Billion valued in 2024.

Developments in formulation technologies have made a substantial contribution to the growth of the topical drug delivery market. These advancements improve the permeability and efficacy of active pharmaceutical ingredients, providing more effective treatment options for a variety of dermatological disorders and encouraging innovation in drug delivery systems. It enables the market to grow at a CAGR of 6.3% from 2024 to 2031.

Topical Drug Delivery Market: Definition/Overview

Topical drug delivery is the process of putting drugs directly into the skin or mucous membranes to treat localized ailments. It enables tailored treatment while reducing overall exposure. Creams, ointments, gels, lotions, and transdermal patches are among the most common topical preparations. Topical drug delivery is commonly used to treat skin conditions such as acne, eczema, and psoriasis. It is also used for delivering drugs to the eyes, nose, ears, and genitals. The primary benefits include increased patient compliance, fewer side effects, and avoidance of first-pass metabolism.

What are the Drivers Influencing the Growth of the Topical Drug Delivery Market?

The rising prevalence of dermatological disorders is a major driver in the topical drug delivery market. According to the Global Burden of Disease report, published in the Journal of Investigative Dermatology, skin illnesses afflicted 1.9 billion people worldwide in 2019. Acne is the most common skin problem in the United States, with up to 50 million people affected each year, according to the American Academy of Dermatology. The growing prevalence of skin problems needs effective topical therapies, which drives the demand for enhanced topical drug delivery systems.

The world's growing older population has a substantial impact on the topical drug delivery market. According to the World Health Organization (WHO), the proportion of the global population over the age of 60 will nearly double between 2015 and 2050, from 12% to 22%. Older people are more vulnerable to a variety of skin problems and chronic diseases that can be treated with topical medicines. For example, the National Institutes of Health (NIH) claims that more than 90% of persons over the age of 65 have at least one chronic illness, many of which can be treated with topical medications.

Furthermore, topical drug delivery technology advancements are fueling market expansion. In 2019, the United States Food and Drug Administration (FDA) authorized 48 new medications, including many with novel delivery mechanisms, such as topical formulations. For example, the FDA's Center for Drug Evaluation and Research (CDER) reported that between 2015 and 2019, dermatological disorders accounted for nearly 8% of all new drug approvals, with many of them using innovative topical delivery systems. This development suggests an increasing demand for novel topical drug delivery systems.

What are the Main Challenges Faced by the Topical Drug Delivery Market?

The restricted capacity of certain formulations to successfully permeate the skin barrier is one of the main barriers to the topical drug delivery market. The skin functions as a protective barrier, preventing many active pharmaceutical ingredients (APIs) from being properly absorbed. This constraint affects the therapeutic efficacy of topical treatments, especially for medicines with large molecular sizes or that are poorly lipid-soluble, limiting their application in clinical practice.

Furthermore, the expansion of the topical drug delivery market is further hampered by increased competition from alternative drug delivery methods such as oral and injectable routes. These options have faster systemic effects and broader applicability, making them more tempting under certain circumstances. As a result, healthcare providers and patients prefer these procedures to topical treatments.

Category-wise Acumens

What Factors Contribute to the Increasing Demand for Semi-solid Formulations?

According to VMR analyst, the semi-solid formulation segment is expected to dominate the segment within the topical drug delivery market during the forecast period. Semi-solid formulations, such as creams and ointments, are popular due to their ease of use. Their consistency enables a smooth spread across the skin, increasing patient compliance. This ease of use makes them especially appealing to people with chronic skin diseases, resulting in increased demand and market dominance.

Semi-solid formulations can effectively transport a diverse range of active medicinal components, including hydrophilic and lipophilic medicines. This versatility allows healthcare professionals to customize treatments for a wide range of dermatological problems, from infections to inflammatory diseases, increasing their popularity and market share in the topical drug delivery market.

Furthermore, semi-solid product formulations allow for better skin penetration and localized action, which can improve therapeutic results. This feature is critical for treating illnesses such as psoriasis and eczema, where precise distribution is required. As a result, the efficacy of semi-solid formulations plays an important role in maintaining their market leadership.

How does Dermal Drug Delivery Propel the Topical Drug Delivery Market?

The dermal drug delivery segment is estimated to hold the largest share of the topical drug delivery market during the forecast period. The rising prevalence of skin disorders such as psoriasis, eczema, and acne has increased demand for dermal drug delivery methods. As more people seek effective treatments for various chronic illnesses, the need for focused topical medicines has grown, resulting in increased market penetration of dermal formulations.

Dermal drug delivery systems are popular because of their ease of use and self-administration capabilities. Patients prefer topical applications to invasive procedures since they can apply therapies at home without the need for medical intervention. This convenience increases patient compliance and fuels the expansion of the dermal drug delivery segment.

Furthermore, continuous advancements in formulation technology, such as improved permeation techniques and innovative delivery systems, have increased the efficacy of dermal drug delivery. These developments enable improved absorption of active substances across the skin barrier, boosting therapy efficacy and broadening the variety of disorders that can be addressed via dermal applications.

Country/Region-wise Acumens

How will the Demand for Topical Drug Delivery in North America Influence the Market?

North America region is estimated to dominate the topical drug delivery market during the forecast period. North America has a large population suffering from numerous skin disorders, which drives the need for topical drug delivery devices. According to the American Academy of Dermatology Association (AAD), psoriasis affects around 7.5 million people in the United States. Also, the National Eczema Association claims that approximately 31 million Americans suffer some form of eczema. These high incidence rates contribute to higher adoption of topical medicines, hence driving market expansion in the region.

Furthermore, the increased prevalence of diabetes in North America is increasing the demand for topical drug delivery devices, especially for wound treatment. According to the Centers for Disease Control and Prevention (CDC), 37.3 million Americans (11.3% of the total population) had diabetes in 2019. Diabetic patients frequently need topical treatments for wound healing and foot care. According to the American Diabetes Association, around 25% of patients with diabetes may develop a foot ulcer over their lifetime, necessitating sophisticated wound care solutions and boosting the topical drug delivery market.

What Factor Contributes to the Growth of Topical Drug Delivery in Asia Pacific?

The Asia Pacific region is estimated to exhibit the highest growth within the topical drug delivery market during the forecast period. The Asia Pacific region is experiencing a considerable increase in skin illnesses, which is boosting demand for topical drug delivery devices. According to the Global Burden of Disease Study, published in the Journal of Investigative Dermatology, the disability-adjusted life years (DALYs) for all skin illnesses in East Asia increased by 33.2% between 1990 and 2017. In Southeast Asia, the growth was much more extreme, reaching 47.6%. For example, a study published in the Journal of the American Academy of Dermatology found that the prevalence of atopic dermatitis in children in various Asian nations is between 20% and 30%, which is higher than the global average of 15-20%.

Furthermore, the Asia Pacific region's increased healthcare expenditure and improved healthcare infrastructure are propelling the topical drug delivery market forward. According to the World Bank, current health expenditure as a proportion of GDP in East Asia and the Pacific rose from 6.4% in 2010 to 7.2% in 2019. In South Asia, it increased from 3.5% to 3.9% over the same period. This increasing healthcare spending has resulted in improved access to innovative medical therapies, such as topical drug delivery systems. For example, in China, healthcare spending per person has more than quadrupled from $289 in 2010 to $535 in 2019, indicating a booming market for pharmaceutical products, including topical treatments.

Competitive Landscape

The topical drug delivery market is characterized by fierce rivalry and the presence of both major pharmaceutical corporations and new players. Established companies have a strong foothold due to their comprehensive product portfolios, large distribution networks, and well-known brand names.

Some of the prominent players operating in the topical drug delivery market include:

Hisamitsu Pharmaceuticals

Bayer AG

Novartis AG

Galderma Holding SA

GlaxoSmithKline PLC

Johnson & Johnson Private Limited

Bausch Health Companies, Inc.

Cipla Limited

3M Company

Merck & Co., Inc.

Crescita Therapeutics, Inc.

Boehringer Ingelheim International GmbH

Pfizer Inc.

Teva Pharmaceutical Industries Ltd.

Glenmark Pharmaceuticals Ltd

Latest Developments:

In February 2021, Aimirall S.A. announced that MC2 Therapeutics granted Almirall exclusive European rights to market Wynzora(R) Cream for plaque psoriasis treatment. MC2 Therapeutics will receive a EUR 15 million upfront payment, sales milestone payments, and double-digit royalties from Wynzora(R) Cream sales in Europe.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Topical Drug Delivery Market, By Product

• Semi-solid formulations
• Liquid formulations
• Solid formulations
• Transdermal products

5. Topical Drug Delivery Market, By Route Of Administration

• Dermal
• Ophthalmic
• Nasal
• Rectal
• Vaginal

6. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

7. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

8. Competitive Landscape

• Key Players
• Market Share Analysis

9. Company Profiles

• Hisamitsu Pharmaceuticals
• Bayer AG
• Novartis AG
• Galderma Holding SA
• GlaxoSmithKline PLC
• Johnson & Johnson Private Limited
• Bausch Health Companies Inc.
• Cipla Limited
• 3M Company
• Merck & Co., Inc.
• Crescita Therapeutics Inc.
• Boehringer Ingelheim International GmbH
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Glenmark Pharmaceuticals Ltd.

10. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

11. Appendix

• List of Abbreviations
• Sources and References